SCHEMBL2019020

SCHEMBL2019020

Cc1nnc(N2CCCC(N)C2)n(Cc2cccc(F)c2)c1=O

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 19/20 0.69
FAP Q12884 1/20 0.51
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019018 1.00 DPP4 (0.69) DPP4FAPCYP3A4
SCHEMBL2024039 0.83 DPP4 (0.77) DPP4FAP
SCHEMBL2023363 0.83 DPP4 (0.77) DPP4CYP3A4
SCHEMBL2024037 0.83 DPP4 (0.77) DPP4FAP
SCHEMBL2023360 0.83 DPP4 (0.77) DPP4CYP3A4
SCHEMBL2020372 0.82 DPP4 (1.00) DPP4FAP
SCHEMBL2020371 0.82 DPP4 (1.00) DPP4FAP
SCHEMBL555121 0.78 DPP4 (0.79) DPP4
SCHEMBL2027764 0.77 DPP4 (0.78) DPP4CYP3A4
SCHEMBL2027763 0.77 DPP4 (0.78) DPP4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340523-B2 Certain dipeptidyl peptidase inhibitors FOCHON PHARMA, INC. (US) 2016-05-17 US disclosed
EP-2521721-B1 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2014-10-01 EP disclosed
US-20140213590-A1 CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS FOCHON PHARMA, INC. (US) 2014-07-31 US disclosed
US-8648073-B2 Certain dipeptidyl peptidase inhibitors FOCHON PHARMA, INC. (US) 2014-02-11 US disclosed
EP-2521721-A1 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS Shanghai Fochon Pharmaceutical Co. Ltd (CN) 2012-11-14 EP disclosed
WO-2011079778-A1 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2011-07-07 WO disclosed
US-20110160212-A1 CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS FOCHON PHARMA, INC. 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160212-A1 CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS DPP4, DPP3, DPP8 DPP4 1/4885FAP 9/4885CYP3A4 520/4885
US-20140213590-A1 CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS DPP4, DPP3, DPP8 DPP4 1/4885FAP 9/4885CYP3A4 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.